Place: Holiday Inn, Bratislava, Slovakia
Date: 8.10.2011
Official languages: Slovak, English

Programme
”Best of ASCO® Slovakia 2011“

www.asco.org/boaintl

Best of ASCO®
A program licensed by the American Society of Clinical Oncology

Annual Meeting’11
Breast Cancer Session
Chairmen: Mária Wágnerová, Ivan Koza (8.35-10.05)

I. Breast Cancer – HER2/ER (Zuzana Syčová-Milá)
1. Abstract #505: TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. (Jenny Chee Ning Chang)
2. Abstract #506: Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer therapy. (Frankie Ann Holmes)
3. Abstract #509: LANDSCAPE: A FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) breast cancer (MBC) before whole brain radiotherapy (WBR). (Thomas Denis Bachelot)

II. Breast Cancer - Triple Negative (Hana Garanová)
1. Abstract #1004: First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high risk early breast cancer (G. Thomas Budd)
2. Abstract #1007: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). (Joyce O’Shaughnessy)
3. Abstract #LBA1005: The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (Harry Douglas Bear)
4. Abstract #LBA1003: Patterns of relapse and toxicity in NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. (Timothy Joseph Whelan)
5. Abstract #1000: Genetic associations with taxane-induced neuropathy by genome-wide association study (GWAS) in E5103. (Bryan P. Schneider)

9.35-10.05 Discussion
10:05-10:25 Coffee Break
Head&Neck Cancer, Melanoma and Glioblastoma Session
Chairmen: Dagmar Sorkovská, Igor Andrašina
(10:25-11:55)

10.25-10:55 III. Head&Neck Cancer (Juraj Beniak)
1. Abstract #5502: A randomized phase 2/3 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial. (Julie A Sosa)
2. Abstract #5500: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). (K. Kian Ang)
3. Abstract #5501: Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study. (Jean-Louise Lefebre)
5. Abstract #LBA5524: Phase III trial of low-level laser therapy to prevent induced oral mucositis in head and neck cancer patients submitted to concurrent chemoradiation. (Héliton Spíndola Antunes)

10:55-11:25 IV. Melanoma and Glioblastoma (Zuzana Hlavatá)
1. Abstract #8505: Randomized phase III trial of high dose interferon alfa-2b (HDI) for four weeks induction only in patients with intermediate and high-risk melanoma (Intergroup trial E 1697). (Sanjiv S. Agarwala)
2. Abstract #8509: BRIM-2: An open-label, multicenter phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. (Antoni Ribas)
3. Abstract #LBA4: Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibition RG7204 with dacarbazine in patients with V600E BRAF mutated melanoma. (Paul B. Chapman)
4. Abstract #LBA5: A phase 3 randomized study of ipilimumab plus dacarbazine versus dacarbazine alone as first line treatment in patients with unresectable stage III or IV melanoma. (Jedd D. Wolchok)
5. Abstract #2006: RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). (Mark R. Gilbert)

11:25-11:55 Discussion

11:55-13:30 Lunch
Genitourinary Cancer and Gynecologic Cancer Session  
Chairmen: Jozef Mardiak, Tibor Packáň (13:30-15:00)

13:30-14:00  
V. Genitourinary Cancer (Michal Mego)

1. Abstract #4503: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results a phase 3 AXIS trial. (Brian Rini)
2. Abstract #4514: A phase III randomized trial of intermittent vs. continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013). (Juanita M. Crook)
3. Abstract #4516: Cabozantinib (XL184) in metastatic castration resistant prostate cancer (mCRPC): Results from a phase 2 randomized discontinuation trial. (Maha Hussain)
4. Abstract #4512: Towards a rational strategy for prostate cancer screening based on long-term risk of prostate cancer metastases and death: Data from a large, unscreened, population-based cohort followed for up to 30 years. (Hans Lilja)
5. Abstract #LBA4517: Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double blind placebo controlled phase 3 study of abiraterone acetate (AA) plus low dose prednisone (P) post docetaxel. (Howard I. Scher)

14:00-14:30  
VI. Gynecologic Cancer (Daniela Matei)

1. Abstract #5003: Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). (Jonathan A. Ledermann)
2. Abstract #LBA5007: OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or Fallopian tube cancer (FTC). (Carol Aghajanian)
3. Abstract #5001: Effect of screening on ovarian cancer mortality in the prostate, lung, colorectal and ovarian (PLCO) cancer randomized screening trial. (Saundra S. Buys)
4. Abstract #5000: Establishing a molecular taxonomy for epithelial ovarian cancer (EOC) from 363 formalin fixed paraffin embedded (FFPE) specimens. (Charlie Gourley)

14:30-15:00  
Discussion
VII. Gastrointestinal (NonColorectal) Cancer (Gabriela Chiorean)
1. Abstract #4003: Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared to bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. (Charles S. Fuchs)
2. Abstract #LBA4002: Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the Phase III CLASSIC trial. (Yung-Jue Bang)
3. Abstract #4004: A multi-center, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). (Se Hoon Park)
5. Abstract #4001: Global Investigation of Therapeutic Decision in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. (Jorge A. Marrero)

VIII. Gastrointestinal (Colorectal) Cancer (Marián Kakalejčík)
1. Abstract #3503: The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSAPB R-04. (Mark S. Roh)
2. Abstract #3504: Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo-)adjuvant chemo-radiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial. (Ralf Hofheinz)
3. Abstract #3507: The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. (Gregory Allen Yothers)
4. Abstract #3510: Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). (Jean-Yves Douillard)
5. Abstract #3511: Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. (Sabine Tejpar)

Discussion
Coffee Break
Programme "Best of ASCO® Slovakia 2011"

Lung Cancer and Patient & Survivor Care Session
Chairman: Peter Kasan, Jozef Chovanec (16:45-17:55)

16:45-17:15  IX. Lung Cancer (Peter Beržinec)
1. Abstract #7002: Randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb) - TREAT. (Michael Kreuter)
3. Abstract #LBA7511: Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) in China (INFORM) (C-TONG 0804). (Li Zhang)
4. Abstract #7503: Erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the european Tarceva vs chemotherapy (EURTAC) phase III randomized trial. (Rafael Rosell)
5. Abstract #LBA 7512: An international, randomized, placebo-controlled, double-blind phase 3 study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). (Giorgio Scagliotti)
6. Abstract #7505: Final efficacy results from OAM4556g, a randomized phase II study evaluating MetMab or placebo in combination with erlotinib in advanced NSCLC. (David R. Spigel)
7. Abstract #7003: Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031. (David Harpole, Jr.)
8. Abstract #CRA7506: Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: The NCI’s lung cancer mutation consortium (LCMC). (Mark G. Kris)

17:15-17:30  X. Patient & Survivor Care (Andrea Škripeková)
1. Abstract #9009: Yoga improves QOL, cortisol rhythm and HRV for women with BREAST CANCER undergoing radiotherapy. (Lorenzo Cohen)
2. Abstract #LBA9014: The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous tromboembolism (VTE) in cancer patients receiving chemotherapy: SAVE ONCO study. (Giancarlo Agnelli)
3. Abstract #9005: Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. (Eva Grunfeld)

17:30-17:55  Discussion

17:55-18.00  FAREWELL
Organizátor / Organizer:
Slovenská onkologická spoločnosť Slovenskej lekárskej spoločnosti

Termin / Date:
8. október 2011 / 8th October 2011

Miesto / Place:
Holiday Inn, Bajkalská 25/A, Bratislava

Predsedajúci, prednášajúci / Faculty:
doc. MUDr. Igor ANDRAŠINA, CSc., VOÚ, Košice, Slovakia
MUDr. Juraj BENIAK, POKO Poprad, Slovakia
doc. MUDr. Peter BERŽINEC, CSc., OÚTaRCH, Nitra, Slovakia
MUDr. Hana Garanová, VOÚ, Košice, Slovakia
MUDr. Zuzana HLAVATÁ, NOÚ, Bratislava, Slovakia
Ass. Prof. Elena G. CHIOREAN, Indiana University Melvin and Bren Simon Cancer Center, USA
MUDr. Jozef Chovanec, POKO sv. Jakuba, Bardejov, Slovakia
MUDr. Marián KAKALEJČIK, POKO Poprad, Slovakia
MUDr. Peter KASAN, Bratislava, Slovakia
prof. MUDr. Ivan KOZA, DrSc., NOÚ, Bratislava, Slovakia
doc. MUDr. Jozef MARDIAK, CSc., NOÚ, Bratislava, Slovakia
Assoc. Prof. Daniela E. MATEI, Indiana University Melvin and Bren Simon Cancer Center, USA
doc. MUDr. Michal MEGO, PhD., NOÚ, Bratislava, Slovakia
MUDr. Tibor PACKAŇ, PhD., VOÚ, Košice, Slovakia
MUDr. Dagmar SORKOVSKÁ, OÚSA, Bratislava, Slovakia
MUDr. Zuzana SYČOVÁ-MILÁ, NOÚ, Bratislava, Slovakia
MUDr. Tomáš ŠÁLEK, NOÚ, Bratislava, Slovakia
MUDr. Andrea ŠKRIPKOVÁ, NOÚ, Bratislava, Slovakia
prof. MUDr. Stanislav ŠPÁNIK, CSc., OÚSA, Bratislava, Slovakia
doc. MUDr. Mária WÁGNEROVÁ, CSc., VOÚ, Košice, Slovakia
prof. MUDr. Stanislav ŠPÁNIK, CSc., OÚSA, Bratislava, Slovakia

doc. MUDr. Mária WÁGNEROVÁ, CSc., VOÚ, Košice, Slovakia

Oficiálny kongresový jazyk / Official conference language:
slovenčina, angličtina / Slovak, English.

Organizačné zabezpečenie / Organizational Management:
SOLEN, s. r. o., Lovínského 16, 811 04 Bratislava

V prípade záujmu o účasť vyplnenú prihlášku zašlite poštou, faxom, e-mailom na adresu: / Completed applications of attendance may be sent by mail, fax or e-mail to the following address:

Ing. Monika Liedlova, SOLEN, s. r. o., Lovínského 16, 811 04 Bratislava
tel.: 02/5413 1365, fax: 02 / 5465 1384, e-mail: liedlova@solensk, www.solensk

Podujatie bude ohodnotené 7 CME kreditmi. / The attendees will receive 7 CME credits.
Surname, Name, Title (legibly):

Work Address:

Tel., fax: e-mail:

Registration number of the Slovak Medical Chamber:

I would like to book a room from 7th to 8th of October 2011

Slovakia Accommodation in the Holiday Inn

I would like to share a room with:

Yes/No

I hereby give permission to the SOLEN Company for the usage of my personal data that is presented in this document, for the purpose of the processing of the application forms and for the distribution for the usage of my personal data that is presented in this document, for the purpose of the processing of the application forms and for the distribution

I hereby give permission to the SOLEN Company for the usage of my personal data that is presented in this document, for the purpose of the processing of the application forms and for the distribution

I hereby give permission to the SOLEN Company for the usage of my personal data that is presented in this document, for the purpose of the processing of the application forms and for the distribution

I hereby give permission to the SOLEN Company for the usage of my personal data that is presented in this document, for the purpose of the processing of the application forms and for the distribution

I hereby give permission to the SOLEN Company for the usage of my personal data that is presented in this document, for the purpose of the processing of the application forms and for the distribution

I hereby give permission to the SOLEN Company for the usage of my personal data that is presented in this document, for the purpose of the processing of the application forms and for the distribution

I hereby give permission to the SOLEN Company for the usage of my personal data that is presented in this document, for the purpose of the processing of the application forms and for the distribution

The deadline for application is 23rd of September 2011 (attendance)